Medical Care
Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Research Report 2024
- Jan 20, 24
- ID: 12673
- Pages: 83
- Figures: 162
- Views: 47
The global B-Cell Maturation Antigen (BCMA) Targeted Therapies market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for B-Cell Maturation Antigen (BCMA) Targeted Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding B-Cell Maturation Antigen (BCMA) Targeted Therapies.
Report Scope
The B-Cell Maturation Antigen (BCMA) Targeted Therapies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the B-Cell Maturation Antigen (BCMA) Targeted Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Transposagen Biopharmaceuticals
Sutro Biopharma
Malin Corporation
Eureka Therapeutics
firstVentury Equity
Five Prime Therapeutics
Credit Suisse Securities
Dana-Farber Cancer Institute
Deerfield Partners
Onyx Pharmaceuticals
Juno Therapeutics
Segment by Type
Bispecific Antibodies
Antibody Drug Conjugates
Chimeric Antigen Receptor T-Cells
Segment by Application
Liver Cancer
Respiratory Cancer
Brain Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of B-Cell Maturation Antigen (BCMA) Targeted Therapies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for B-Cell Maturation Antigen (BCMA) Targeted Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding B-Cell Maturation Antigen (BCMA) Targeted Therapies.
Report Scope
The B-Cell Maturation Antigen (BCMA) Targeted Therapies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the B-Cell Maturation Antigen (BCMA) Targeted Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Transposagen Biopharmaceuticals
Sutro Biopharma
Malin Corporation
Eureka Therapeutics
firstVentury Equity
Five Prime Therapeutics
Credit Suisse Securities
Dana-Farber Cancer Institute
Deerfield Partners
Onyx Pharmaceuticals
Juno Therapeutics
Segment by Type
Bispecific Antibodies
Antibody Drug Conjugates
Chimeric Antigen Receptor T-Cells
Segment by Application
Liver Cancer
Respiratory Cancer
Brain Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of B-Cell Maturation Antigen (BCMA) Targeted Therapies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Bispecific Antibodies
1.2.3 Antibody Drug Conjugates
1.2.4 Chimeric Antigen Receptor T-Cells
1.3 Market by Application
1.3.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Liver Cancer
1.3.3 Respiratory Cancer
1.3.4 Brain Cancer
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Perspective (2019-2030)
2.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Growth Trends by Region
2.2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size by Region (2019-2024)
2.2.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Region (2025-2030)
2.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Dynamics
2.3.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry Trends
2.3.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers
2.3.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Challenges
2.3.4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players by Revenue
3.1.1 Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players by Revenue (2019-2024)
3.1.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Players (2019-2024)
3.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue
3.4 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Concentration Ratio
3.4.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in 2023
3.5 B-Cell Maturation Antigen (BCMA) Targeted Therapies Key Players Head office and Area Served
3.6 Key Players B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Solution and Service
3.7 Date of Enter into B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Breakdown Data by Type
4.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size by Type (2019-2024)
4.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Type (2025-2030)
5 B-Cell Maturation Antigen (BCMA) Targeted Therapies Breakdown Data by Application
5.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size by Application (2019-2024)
5.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2019-2030)
6.2 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024)
6.4 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2019-2030)
7.2 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024)
7.4 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2019-2030)
8.2 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2019-2024)
8.4 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2019-2030)
9.2 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024)
9.4 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2019-2030)
10.2 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024)
10.4 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Transposagen Biopharmaceuticals
11.1.1 Transposagen Biopharmaceuticals Company Detail
11.1.2 Transposagen Biopharmaceuticals Business Overview
11.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.1.4 Transposagen Biopharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.1.5 Transposagen Biopharmaceuticals Recent Development
11.2 Sutro Biopharma
11.2.1 Sutro Biopharma Company Detail
11.2.2 Sutro Biopharma Business Overview
11.2.3 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.2.4 Sutro Biopharma Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.2.5 Sutro Biopharma Recent Development
11.3 Malin Corporation
11.3.1 Malin Corporation Company Detail
11.3.2 Malin Corporation Business Overview
11.3.3 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.3.4 Malin Corporation Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.3.5 Malin Corporation Recent Development
11.4 Eureka Therapeutics
11.4.1 Eureka Therapeutics Company Detail
11.4.2 Eureka Therapeutics Business Overview
11.4.3 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.4.4 Eureka Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.4.5 Eureka Therapeutics Recent Development
11.5 firstVentury Equity
11.5.1 firstVentury Equity Company Detail
11.5.2 firstVentury Equity Business Overview
11.5.3 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.5.4 firstVentury Equity Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.5.5 firstVentury Equity Recent Development
11.6 Five Prime Therapeutics
11.6.1 Five Prime Therapeutics Company Detail
11.6.2 Five Prime Therapeutics Business Overview
11.6.3 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.6.4 Five Prime Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.6.5 Five Prime Therapeutics Recent Development
11.7 Credit Suisse Securities
11.7.1 Credit Suisse Securities Company Detail
11.7.2 Credit Suisse Securities Business Overview
11.7.3 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.7.4 Credit Suisse Securities Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.7.5 Credit Suisse Securities Recent Development
11.8 Dana-Farber Cancer Institute
11.8.1 Dana-Farber Cancer Institute Company Detail
11.8.2 Dana-Farber Cancer Institute Business Overview
11.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.8.4 Dana-Farber Cancer Institute Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.8.5 Dana-Farber Cancer Institute Recent Development
11.9 Deerfield Partners
11.9.1 Deerfield Partners Company Detail
11.9.2 Deerfield Partners Business Overview
11.9.3 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.9.4 Deerfield Partners Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.9.5 Deerfield Partners Recent Development
11.10 Onyx Pharmaceuticals
11.10.1 Onyx Pharmaceuticals Company Detail
11.10.2 Onyx Pharmaceuticals Business Overview
11.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.10.4 Onyx Pharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.10.5 Onyx Pharmaceuticals Recent Development
11.11 Juno Therapeutics
11.11.1 Juno Therapeutics Company Detail
11.11.2 Juno Therapeutics Business Overview
11.11.3 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.11.4 Juno Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.11.5 Juno Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Bispecific Antibodies
1.2.3 Antibody Drug Conjugates
1.2.4 Chimeric Antigen Receptor T-Cells
1.3 Market by Application
1.3.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Liver Cancer
1.3.3 Respiratory Cancer
1.3.4 Brain Cancer
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Perspective (2019-2030)
2.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Growth Trends by Region
2.2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size by Region (2019-2024)
2.2.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Region (2025-2030)
2.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Dynamics
2.3.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry Trends
2.3.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers
2.3.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Challenges
2.3.4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players by Revenue
3.1.1 Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players by Revenue (2019-2024)
3.1.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Players (2019-2024)
3.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue
3.4 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Concentration Ratio
3.4.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in 2023
3.5 B-Cell Maturation Antigen (BCMA) Targeted Therapies Key Players Head office and Area Served
3.6 Key Players B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Solution and Service
3.7 Date of Enter into B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Breakdown Data by Type
4.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size by Type (2019-2024)
4.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Type (2025-2030)
5 B-Cell Maturation Antigen (BCMA) Targeted Therapies Breakdown Data by Application
5.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size by Application (2019-2024)
5.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2019-2030)
6.2 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024)
6.4 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2019-2030)
7.2 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024)
7.4 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2019-2030)
8.2 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2019-2024)
8.4 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2019-2030)
9.2 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024)
9.4 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2019-2030)
10.2 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024)
10.4 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Transposagen Biopharmaceuticals
11.1.1 Transposagen Biopharmaceuticals Company Detail
11.1.2 Transposagen Biopharmaceuticals Business Overview
11.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.1.4 Transposagen Biopharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.1.5 Transposagen Biopharmaceuticals Recent Development
11.2 Sutro Biopharma
11.2.1 Sutro Biopharma Company Detail
11.2.2 Sutro Biopharma Business Overview
11.2.3 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.2.4 Sutro Biopharma Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.2.5 Sutro Biopharma Recent Development
11.3 Malin Corporation
11.3.1 Malin Corporation Company Detail
11.3.2 Malin Corporation Business Overview
11.3.3 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.3.4 Malin Corporation Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.3.5 Malin Corporation Recent Development
11.4 Eureka Therapeutics
11.4.1 Eureka Therapeutics Company Detail
11.4.2 Eureka Therapeutics Business Overview
11.4.3 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.4.4 Eureka Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.4.5 Eureka Therapeutics Recent Development
11.5 firstVentury Equity
11.5.1 firstVentury Equity Company Detail
11.5.2 firstVentury Equity Business Overview
11.5.3 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.5.4 firstVentury Equity Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.5.5 firstVentury Equity Recent Development
11.6 Five Prime Therapeutics
11.6.1 Five Prime Therapeutics Company Detail
11.6.2 Five Prime Therapeutics Business Overview
11.6.3 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.6.4 Five Prime Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.6.5 Five Prime Therapeutics Recent Development
11.7 Credit Suisse Securities
11.7.1 Credit Suisse Securities Company Detail
11.7.2 Credit Suisse Securities Business Overview
11.7.3 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.7.4 Credit Suisse Securities Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.7.5 Credit Suisse Securities Recent Development
11.8 Dana-Farber Cancer Institute
11.8.1 Dana-Farber Cancer Institute Company Detail
11.8.2 Dana-Farber Cancer Institute Business Overview
11.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.8.4 Dana-Farber Cancer Institute Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.8.5 Dana-Farber Cancer Institute Recent Development
11.9 Deerfield Partners
11.9.1 Deerfield Partners Company Detail
11.9.2 Deerfield Partners Business Overview
11.9.3 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.9.4 Deerfield Partners Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.9.5 Deerfield Partners Recent Development
11.10 Onyx Pharmaceuticals
11.10.1 Onyx Pharmaceuticals Company Detail
11.10.2 Onyx Pharmaceuticals Business Overview
11.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.10.4 Onyx Pharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.10.5 Onyx Pharmaceuticals Recent Development
11.11 Juno Therapeutics
11.11.1 Juno Therapeutics Company Detail
11.11.2 Juno Therapeutics Business Overview
11.11.3 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.11.4 Juno Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.11.5 Juno Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Bispecific Antibodies
Table 3. Key Players of Antibody Drug Conjugates
Table 4. Key Players of Chimeric Antigen Receptor T-Cells
Table 5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Region (2019-2024)
Table 9. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Region (2025-2030)
Table 11. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Trends
Table 12. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers
Table 13. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Challenges
Table 14. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints
Table 15. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Players (2019-2024)
Table 17. Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies as of 2023)
Table 18. Ranking of Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Solution and Service
Table 22. Date of Enter into B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Type (2019-2024)
Table 26. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Type (2025-2030)
Table 28. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Application (2019-2024)
Table 30. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Application (2025-2030)
Table 32. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 47. Transposagen Biopharmaceuticals Company Detail
Table 48. Transposagen Biopharmaceuticals Business Overview
Table 49. Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 50. Transposagen Biopharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 51. Transposagen Biopharmaceuticals Recent Development
Table 52. Sutro Biopharma Company Detail
Table 53. Sutro Biopharma Business Overview
Table 54. Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 55. Sutro Biopharma Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 56. Sutro Biopharma Recent Development
Table 57. Malin Corporation Company Detail
Table 58. Malin Corporation Business Overview
Table 59. Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 60. Malin Corporation Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 61. Malin Corporation Recent Development
Table 62. Eureka Therapeutics Company Detail
Table 63. Eureka Therapeutics Business Overview
Table 64. Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 65. Eureka Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 66. Eureka Therapeutics Recent Development
Table 67. firstVentury Equity Company Detail
Table 68. firstVentury Equity Business Overview
Table 69. firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 70. firstVentury Equity Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 71. firstVentury Equity Recent Development
Table 72. Five Prime Therapeutics Company Detail
Table 73. Five Prime Therapeutics Business Overview
Table 74. Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 75. Five Prime Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 76. Five Prime Therapeutics Recent Development
Table 77. Credit Suisse Securities Company Detail
Table 78. Credit Suisse Securities Business Overview
Table 79. Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 80. Credit Suisse Securities Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 81. Credit Suisse Securities Recent Development
Table 82. Dana-Farber Cancer Institute Company Detail
Table 83. Dana-Farber Cancer Institute Business Overview
Table 84. Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 85. Dana-Farber Cancer Institute Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 86. Dana-Farber Cancer Institute Recent Development
Table 87. Deerfield Partners Company Detail
Table 88. Deerfield Partners Business Overview
Table 89. Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 90. Deerfield Partners Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 91. Deerfield Partners Recent Development
Table 92. Onyx Pharmaceuticals Company Detail
Table 93. Onyx Pharmaceuticals Business Overview
Table 94. Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 95. Onyx Pharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 96. Onyx Pharmaceuticals Recent Development
Table 97. Juno Therapeutics Company Detail
Table 98. Juno Therapeutics Business Overview
Table 99. Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 100. Juno Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 101. Juno Therapeutics Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Type: 2023 VS 2030
Figure 3. Bispecific Antibodies Features
Figure 4. Antibody Drug Conjugates Features
Figure 5. Chimeric Antigen Receptor T-Cells Features
Figure 6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Application: 2023 VS 2030
Figure 8. Liver Cancer Case Studies
Figure 9. Respiratory Cancer Case Studies
Figure 10. Brain Cancer Case Studies
Figure 11. Others Case Studies
Figure 12. B-Cell Maturation Antigen (BCMA) Targeted Therapies Report Years Considered
Figure 13. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Region: 2023 VS 2030
Figure 16. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Players in 2023
Figure 17. Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in 2023
Figure 19. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Country (2019-2030)
Figure 21. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Country (2019-2030)
Figure 25. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Region (2019-2030)
Figure 33. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Country (2019-2030)
Figure 41. Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Country (2019-2030)
Figure 45. Turkey B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Transposagen Biopharmaceuticals Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 48. Sutro Biopharma Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 49. Malin Corporation Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 50. Eureka Therapeutics Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 51. firstVentury Equity Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 52. Five Prime Therapeutics Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 53. Credit Suisse Securities Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 54. Dana-Farber Cancer Institute Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 55. Deerfield Partners Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 56. Onyx Pharmaceuticals Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 57. Juno Therapeutics Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Table 1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Bispecific Antibodies
Table 3. Key Players of Antibody Drug Conjugates
Table 4. Key Players of Chimeric Antigen Receptor T-Cells
Table 5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Region (2019-2024)
Table 9. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Region (2025-2030)
Table 11. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Trends
Table 12. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers
Table 13. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Challenges
Table 14. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints
Table 15. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Players (2019-2024)
Table 17. Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies as of 2023)
Table 18. Ranking of Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Solution and Service
Table 22. Date of Enter into B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Type (2019-2024)
Table 26. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Type (2025-2030)
Table 28. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Application (2019-2024)
Table 30. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Application (2025-2030)
Table 32. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 47. Transposagen Biopharmaceuticals Company Detail
Table 48. Transposagen Biopharmaceuticals Business Overview
Table 49. Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 50. Transposagen Biopharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 51. Transposagen Biopharmaceuticals Recent Development
Table 52. Sutro Biopharma Company Detail
Table 53. Sutro Biopharma Business Overview
Table 54. Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 55. Sutro Biopharma Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 56. Sutro Biopharma Recent Development
Table 57. Malin Corporation Company Detail
Table 58. Malin Corporation Business Overview
Table 59. Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 60. Malin Corporation Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 61. Malin Corporation Recent Development
Table 62. Eureka Therapeutics Company Detail
Table 63. Eureka Therapeutics Business Overview
Table 64. Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 65. Eureka Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 66. Eureka Therapeutics Recent Development
Table 67. firstVentury Equity Company Detail
Table 68. firstVentury Equity Business Overview
Table 69. firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 70. firstVentury Equity Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 71. firstVentury Equity Recent Development
Table 72. Five Prime Therapeutics Company Detail
Table 73. Five Prime Therapeutics Business Overview
Table 74. Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 75. Five Prime Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 76. Five Prime Therapeutics Recent Development
Table 77. Credit Suisse Securities Company Detail
Table 78. Credit Suisse Securities Business Overview
Table 79. Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 80. Credit Suisse Securities Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 81. Credit Suisse Securities Recent Development
Table 82. Dana-Farber Cancer Institute Company Detail
Table 83. Dana-Farber Cancer Institute Business Overview
Table 84. Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 85. Dana-Farber Cancer Institute Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 86. Dana-Farber Cancer Institute Recent Development
Table 87. Deerfield Partners Company Detail
Table 88. Deerfield Partners Business Overview
Table 89. Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 90. Deerfield Partners Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 91. Deerfield Partners Recent Development
Table 92. Onyx Pharmaceuticals Company Detail
Table 93. Onyx Pharmaceuticals Business Overview
Table 94. Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 95. Onyx Pharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 96. Onyx Pharmaceuticals Recent Development
Table 97. Juno Therapeutics Company Detail
Table 98. Juno Therapeutics Business Overview
Table 99. Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
Table 100. Juno Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024) & (US$ Million)
Table 101. Juno Therapeutics Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Type: 2023 VS 2030
Figure 3. Bispecific Antibodies Features
Figure 4. Antibody Drug Conjugates Features
Figure 5. Chimeric Antigen Receptor T-Cells Features
Figure 6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Application: 2023 VS 2030
Figure 8. Liver Cancer Case Studies
Figure 9. Respiratory Cancer Case Studies
Figure 10. Brain Cancer Case Studies
Figure 11. Others Case Studies
Figure 12. B-Cell Maturation Antigen (BCMA) Targeted Therapies Report Years Considered
Figure 13. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Region: 2023 VS 2030
Figure 16. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Players in 2023
Figure 17. Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in 2023
Figure 19. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Country (2019-2030)
Figure 21. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Country (2019-2030)
Figure 25. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Region (2019-2030)
Figure 33. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Country (2019-2030)
Figure 41. Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Country (2019-2030)
Figure 45. Turkey B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Transposagen Biopharmaceuticals Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 48. Sutro Biopharma Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 49. Malin Corporation Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 50. Eureka Therapeutics Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 51. firstVentury Equity Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 52. Five Prime Therapeutics Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 53. Credit Suisse Securities Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 54. Dana-Farber Cancer Institute Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 55. Deerfield Partners Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 56. Onyx Pharmaceuticals Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 57. Juno Therapeutics Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Smart Potentiometric Titrator - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Multifunctional Zeta Potential Analyzer - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Ultrapure Water pH Sensor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232